Mylan NV (MYL) finalized a $465 million settlement with the U.S. Department of Justice, bringing an end to a suit over claims the drug maker overcharged the government for its EpiPen emergency allergy treatment, Reuters reported.

The U.S. Attorney's Office in Massachusetts revealed the deal Thursday, 10 months after it was solidified. Mylan maintained it had done nothing wrong, but the government said taxpayers expect "companies like Mylan that receive payments from taxpayer-funded programs to scrupulously follow the rules."

The government claimed Mylan misclassified the EpiPen as a generic rather than a branded prescription to avoid paying rebates to Medicaid after French rival Sanofi SA (SNY) went to the authorities in 2015. Sanofi will get nearly $38.8 million as a reward from the government.

Mylan stock traded up 1.5% to $30.93 midday Thursday.

Mylan isn't the only drug maker working itself out of hot water. Valeant (VRX) still has to prove it can pay down its debt. 

More of What's Trending on TheStreet:

More from Stocks

Lee Munson on the Market, Trade and the Possibility of a Recession

Lee Munson on the Market, Trade and the Possibility of a Recession

Buy These 3 Killer Tech Stocks, Says Wall Street's #1 Analyst

Buy These 3 Killer Tech Stocks, Says Wall Street's #1 Analyst

How Tariffs Can Impact the U.S. and the Global Capital Markets

How Tariffs Can Impact the U.S. and the Global Capital Markets

Here's Why Alphabet, Facebook and Amazon Earnings May Overshadow Tariff Worries

Here's Why Alphabet, Facebook and Amazon Earnings May Overshadow Tariff Worries

Trump's Attack on the Federal Reserve and China Leaves Investors Feeling Strange

Trump's Attack on the Federal Reserve and China Leaves Investors Feeling Strange